So James, can you tell us what led to this interesting idea, and why do you think this would be an interesting approach in the near future or perhaps has already started?

So before I get there, I'll just step in and correct one thing you said, that each cancer has its epigenome signature.

Every cell type in the body has a unique epigenetic signature.

When we're doing cancer tissue of origin, we're actually detecting the cell type origin signal.

There's a cancer signal as well, but it's, it's separate and distinct.

And so for our toxicity monitoring, it's that tissue, exquisitely specific tissue signal we're looking for each time.

This work from my side started probably six or seven years ago with a conversation with a colleague in a different part of AstraZeneca, our respiratory medicine space.

How do you see that from a futuristic standpoint? This is a very complex question, I understand that part, but where does this go if you look at how the MRD assessments have gone in the last five years?